We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The tumor therapy landscape of synthetic lethality.
- Authors
Zhang, Biyu; Tang, Chen; Yao, Yanli; Chen, Xiaohan; Zhou, Chi; Wei, Zhiting; Xing, Feiyang; Chen, Lan; Cai, Xiang; Zhang, Zhiyuan; Sun, Shuyang; Liu, Qi
- Abstract
Synthetic lethality is emerging as an important cancer therapeutic paradigm, while the comprehensive selective treatment opportunities for various tumors have not yet been explored. We develop the Synthetic Lethality Knowledge Graph (SLKG), presenting the tumor therapy landscape of synthetic lethality (SL) and synthetic dosage lethality (SDL). SLKG integrates the large-scale entity of different tumors, drugs and drug targets by exploring a comprehensive set of SL and SDL pairs. The overall therapy landscape is prioritized to identify the best repurposable drug candidates and drug combinations with literature supports, in vitro pharmacologic evidence or clinical trial records. Finally, cladribine, an FDA-approved multiple sclerosis treatment drug, is selected and identified as a repurposable drug for treating melanoma with CDKN2A mutation by in vitro validation, serving as a demonstrating SLKG utility example for novel tumor therapy discovery. Collectively, SLKG forms the computational basis to uncover cancer-specific susceptibilities and therapy strategies based on the principle of synthetic lethality. Various methods have been proposed to identify synthetic lethality interactions, but selective treatment opportunities for various tumors have not yet been explored. Here, the authors develop the Synthetic Lethality Knowledge Graph webserver (SLKG, http://www.slkg.net) to explore the comprehensive tumor therapy landscape and uncover cancer-specific susceptibilities based on the principle of synthetic lethality.
- Subjects
KNOWLEDGE graphs; LANDSCAPES; TUMORS; TARGETED drug delivery; MULTIPLE sclerosis; SYNTHETIC biology; CYCLIN-dependent kinase inhibitor-2A; BRAF genes; NATALIZUMAB
- Publication
Nature Communications, 2021, Vol 12, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-021-21544-2